Coherus Biosciences expects to launch a pegfilgrastim biosimilar in 2018. Other biosimilars in its pipeline include those referencing Lucentis, or ranibizumab; Eylea, or aflibercept; Humira, or adalimumab; and Enbrel, or etanercept.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.